Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy

Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy

Abstract The first approved vaccines for human use against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) are nanotechnology‐based. Although they are modular, rapidly produced, and can reduce disease severity, the currently available vaccines are restricted in preventing infection, str...

Full description

Saved in:
Bibliographic Details
Main Authors: Rita C. Acúrcio, Ron Kleiner, Daniella Vaskovich‐Koubi, Bárbara Carreira, Yulia Liubomirski, Carolina Palma, Adva Yeheskel, Eilam Yeini, Ana S. Viana, Vera Ferreira, Carlos Araújo, Michael Mor, Natalia T. Freund, Eran Bacharach, João Gonçalves, Mira Toister‐Achituv, Manon Fabregue, Solene Matthieu, Capucine Guerry, Ana Zarubica, Sarit Aviel‐Ronen, Helena F. Florindo, Ronit Satchi‐Fainaro
Format: Article
Language:English
Published: Wiley 2024-10-01
Series:Advanced Science
Subjects:
Dendritic cells
Intranasal
MHC class I and MHC class II peptides
Nanovaccines
PD‐1/PD‐L1 immune checkpoints
SARS‐CoV‐2
Online Access:https://doi.org/10.1002/advs.202404159
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/advs.202404159

Similar Items